Drug Search Results

Inolimomab

Alternative Names: inolimomab, Leukotac
Latest Update: 2023-06-20
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: IL2 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: ElsaLys Biotech
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Inolimomab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Graft vs Host Disease|Allogeneic Stem Cell Transplant

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
EiFFEL	P3	Unknown status	Graft vs Host Disease	2022-12-01	74%
2007-005009-24	P3	Completed	Graft vs Host Disease\|Allogeneic Stem Cell Transplant	2015-02-16
2006-005019-81	P2	Active, not recruiting	Allogeneic Stem Cell Transplant\|Graft vs Host Disease	2008-05-27
ATUC-LKT	N/A	Available	Graft vs Host Disease	None

Recent News Events

Date	Type	Title
06/20/2023	PubMed	Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials.
09/21/2021	PubMed	Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease.
04/15/2021	News Article	While ElsaLys continues to work on the filing of marketing approval in Europe and the U.S. for inolimomab, the company confirms the renew of its cohort ATU in France and compassionate use programs submissions in several other countries
03/05/2021	PubMed	Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.
01/19/2021	News Article	Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease
01/19/2021	News Article	Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease
07/23/2020	News Article	ElsaLys Biotech announces submission of Biologics License Application to FDA for LEUKOTAC® (inolimomab) for the treatment of graft-versus-host disease in adult patients

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions